Clio A Harper

  • Source: Scopus
  • Calculated based on no. of publications stored in Pure and citations from Scopus
1987 …2022

Research activity per year

If you made any changes in Pure these will be visible here soon.

Search results

  • 2022

    Low-Dose Bevacizumab - But What about Long-term Results?

    Harper, C. A., Beck, K. D. & Moshfeghi, D. M., Mar 2022, In: JAMA Ophthalmology. 140, 3, p. 287-288 2 p.

    Research output: Contribution to journalLetterpeer-review

  • 2017

    To the editor

    Todorich, B., Thanos, A., Yonekawa, Y., Thomas, B. J., Faia, L. J., Chang, E., Shulman, J., Olsen, K. R., Blair, M. P., Shapiro, M. P., Ferrone, P., Vajzovic, L., Toth, C. A., Lee, T. C., Robinson, J., Hubbard, B., Kondo, H., Besirli, C. G., Nudleman, E., Wong, S. C. & 27 others, Kusaka, S., Walsh, M., Chan, R. V. P., Berrocal, A., Caputo, G., Murray, T. G., Sears, J., Schunemann, R., Harper, C. A., Kychental, A., Dorta, P., Cernichiaro-Espinosa, L. A., Wu, W. C., Campbell, J. P., Martinez-Castellanos, M. A., Quiroz-Mercado, H., Hayashi, H., Quiram, P., Amphornphruet, A., Hartnett, M. E., Tsui, I., Ells, A., John, V., Moshfeghi, D., Capone, A., Drenser, K. A. & Trese, M. T., 2017, In: Retina. 37, 5, p. e52-e54

    Research output: Contribution to journalLetterpeer-review